Nicholas Donoghoe Biography and Net Worth

SVP of AbbVie


As Senior Vice President, R&D Chief Operating Officer Nicholas Donoghoe oversees the operational and strategic execution of our pipeline across the R&D organization. In addition, Dr. Donoghoe leads the portfolio wide capability building that increase AbbVie’s agility, speed and cross-functional execution to unlock the full potential of our portfolio.

Dr. Donoghoe joined AbbVie in 2019 in a newly created Innovation role to support corporate growth through cross-functional efforts across the company.  In 2020, he then led Global Strategy and Operations for Allergan Aesthetics with responsibility for pipeline marketing, customer service, analytics, and commercial strategy.

In 2021, Nicholas was asked to lead Portfolio Innovation across both the Aesthetics and Therapeutics businesses to define and implement transformational initiatives that directly impact short- and long-term goals and the future success of AbbVie.

Dr. Donoghoe views his work through a unique lens of business and scientific acumen, having served as a partner at McKinsey and holding an M.D. from Johns Hopkins University and a B.S. from Duke University. During his time at McKinsey, he served global clients across a broad range of geographies and therapeutic areas, including oncology, immunology, and neuroscience. 

What is Nicholas Donoghoe's net worth?

The estimated net worth of Nicholas Donoghoe is at least $1.76 million as of August 29th, 2019. Dr. Donoghoe owns 13,090 shares of AbbVie stock worth more than $1,756,809 as of September 30th. This net worth approximation does not reflect any other assets that Dr. Donoghoe may own. Learn More about Nicholas Donoghoe's net worth.

How do I contact Nicholas Donoghoe?

The corporate mailing address for Dr. Donoghoe and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Nicholas Donoghoe's contact information.

Has Nicholas Donoghoe been buying or selling shares of AbbVie?

Nicholas Donoghoe has not been actively trading shares of AbbVie during the past quarter. Most recently, on Thursday, August 29th, Nicholas Donoghoe bought 7,525 shares of AbbVie stock. The stock was acquired at an average cost of $66.19 per share, with a total value of $498,079.75. Following the completion of the transaction, the senior vice president now directly owns 13,090 shares of the company's stock, valued at $866,427.10. Learn More on Nicholas Donoghoe's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 17 times. They sold a total of 1,048,944 shares worth more than $146,558,841.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Nicholas Donoghoe Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2019Buy7,525$66.19$498,079.7513,090View SEC Filing Icon  
See Full Table

Nicholas Donoghoe Buying and Selling Activity at AbbVie

This chart shows Nicholas Donoghoe's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $134.21
Low: $134.09
High: $142.33

50 Day Range

MA: $141.00
Low: $134.21
High: $151.15

2 Week Range

Now: $134.21
Low: $106.86
High: $175.91

Volume

15,336,473 shs

Average Volume

6,873,221 shs

Market Capitalization

$237.30 billion

P/E Ratio

19.01

Dividend Yield

3.95%

Beta

0.72
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy:
The One Ticker Retirement Plan… How to make all the money you need – in any market – using a single stock. Click here for the name of the ticker…
>>>
pixel